When a scientific trial ends with the experimental product proving to be ineffective, it is easy to say that the trial was a failure. This was one of the responses to the news that the world's first Phase III vaccine trial, which tested AIDSVAX®, showed no protection overall (for more on scientific data, see above). But this is not the whole story: at least some success can be measured in how a trial was conducted; how many volunteers remained through the end of the study; and how volunteers' behaviors and beliefs were affected by the trial. Here, the AIDSVAX® trial provided some good news, and some interesting lessons.

Before the trial began, many scientists doubted whether enough high-risk volunteers could be recruited at North American and European clinical study sites to establish a trial population, also called a cohort, with sufficiently high infection rates (incidence) and stability to meet the trial requirements. The trial followed volunteers for three years, and called for 7 immunizations.

But both the incidence and retention rates for the trial proved these fears unfounded. The trial enrolled over 5,100 men and 309 women. At the end of the 3 year study, VaxGen reported an incidence of 2.7% in men and 0.8% in women. The company also reported a retention rate of over 80%, a figure which is considered a success for a trial occurring over such an extended time period. These retention rates are particularly striking in the trial's high-risk women, most of whom live marginalized lives: the majority are poor, use drugs, exchange sex for shelter or money, and have unstable housing situations. During the study, many were also arrested and spent time in prisons and jails. Against this stark backdrop, the women and the trial site staff established durable, trusting relationships, reflected in the over 80% retention rates.

Another early concern was that trial participation would dramatically change volunteers' frequency of risk behavior. On the one hand, participants might assume that the vaccine is protective and therefore increase their risk behaviors. On the other hand, the risk reduction counseling that volunteers receive at each study visit might lead to greatly reduced rates of risk behaviors, which could lower HIV incidence to the point where it becomes impossible to get a scientifically reliable answer on the vaccine's ability to protect.

In the end, neither of these scenarios came to pass. Three years after enrolling in the trial, men and women reported rates of high-risk behavior that were at or just below those reported at the beginning of the trial.

These were overall data. There were other studies asking more specific questions, such as whether volunteers' beliefs about whether they received the vaccine or placebo affected risk behavior. The trial was blinded, meaning that neither volunteers nor staff actually knew who received the vaccine or the placebo. In spite of this, volunteers made assumptions about what they had received. Researchers at the U.S. Centers for Disease Control and Prevention (CDC) found that these assumptions changed rates of risk behavior.

The CDC team grouped volunteers by whether they believed they had received the vaccine, the placebo or had no fixed idea about what they received. For the men who have sex with men, volunteers who thought they had received the vaccine reported consistently higher rates of unprotected anal intercourse than men who believed they had received the placebo or did not know. In contrast, at the 12 and 24 month visits, women who thought they had received the placebo had higher rates of risk behavior than those who thought they were given vaccine.

So despite the trial's overall successes with recruitment and retention, there are areas for improvement in future studies. Even when trial staff repeatedly explained that the vaccine was experimental and might not provide any protection at all, some people still leapt to conclusions about being protected—without knowing whether they had received the vaccine or not. Data from the women volunteers (a group with less education than the men) suggests that there may have been some confusion around the terms "vaccine" and "placebo." Both findings highlight the need for clear, ongoing, audience-appropriate education and information for vaccine trial volunteers.


In an article titled, "The Need for a Global Vaccine Enterprise" (Science: 300:2039;2003), 24 of the world's leading vaccine researchers and advocates called for a major effort to expand and restructure the search for an AIDS vaccine. Richard Klausner, Executive Director of the Bill and Melinda Gates Foundation global health program, was lead author on the paper.

The proposal calls for a coordinated effort similar to the Human Genome Project, in which an international group of scientists agreed on a scientific road map and voluntarily divided tasks. Similarly, this new vaccine enterprise would systematically identify critical tasks, allocate funds and ensure that participating teams of researchers collectively covered the entire range of potential vaccine approaches. To accomplish this, the enterprise would establish new Vaccine Development Centers (VDCs). These could be actual institutes, collaborations or consortia between existing groups, and could also include efforts sponsored by existing funders, such as the National Institutes of Health, IAVI and the European Union—all of whom were signatories to the article.

The VDCs would be part of an interconnected network that also includes manufacturing facilities, central laboratories, and clinical trial sites capable of enrolling a projected figure of 35,000 volunteers into clinical studies each year. The paper did not specify funding requirements or sources for this massive endeavor, and many details still need to be filled in. At press time, major vaccine stakeholders were planning an August meeting, hosted by the Bill & Melinda Gates Foundation, to discuss the next steps.


In March, the European Union officially launched a new collaboration called the European and Developing Countries Clinical Trials Partnership (EDCTP), to help prepare for large-scale clinical studies of strategies to treat and prevent the major infectious disease killers in the developing world: HIV, tuberculosis and malaria. The money will be used to fund these studies, which may require thousands of volunteers, hundreds of medical personnel and countless data collection forms, as well as physical facilities and equipment.

The EDCTP will link many of Europe's major research institutions, and will build on already existing links between these groups and African sites. Like other efforts underway in this arena, the EDCTP will focus on strengthening capacity for AIDS vaccines and other therapeutic and preventive measures—including drugs, vaccines and microbicides.

The program comes with a funding commitment of €200 million for 2003-2008, but its planners hope for the equivalent of another €400 million in institutional support from research partners, and additional donations from government and private sector sources. Priorities and agendas for the EDCTP will be set by a partnership board of 12 researchers from Africa and Europe. The EDCTP will have a secretariat in the Hague and another at an African location, yet to be determined.


VaxGen's Phase III results brought attention to the question of whether a vaccine might work differently in different populations. Although inconclusive, the study's data raised questions about different levels of protection in various racial groups and in men and women. Discussions of potential differences between the sexes have led some scientists to re-examine a few previous studies which showed some evidence that vaccines might work differently in men and women.

The first indication of a possible gender gap in vaccine protection came in 2000 from two Phase III trials of a candidate vaccine against a strain of herpes virus (called HSV-2), which causes genital lesions. Among women who did not carry any other herpes viruses, the vaccine was 75% effective in preventing symptomatic disease. But among men, no protection was seen.

However, as with the VaxGen trial, the number of women in the HSV-2 studies was too small for firm conclusions to be drawn. So in November 2002 the vaccine's developer, GlaxoSmithKline, launched a second larger trial in 6,000 women, to find out whether the observation holds up.

If this trial confirms the initial trend, then the world could have its first sexspecific vaccine on its hands.

Historically, there's been no indication of gender or racial differences in how well vaccines work. Globally, millions of men, women, boys and girls of all races have been immunized against diseases, like measles, mumps, polio and tetanus. Yet there has been very little evidence of subgroup-specific effects for any of them.

So why are apparent differences emerging? Perhaps because the vaccines in question are targetting sexually-transmitted diseases (STDs). STDs start in the genital tract, which is the site of the most dramatic differences in men's and women's bodies, including distinct tissue types and immune defenses. These differences have long been linked to men's and women's varying symptoms from and susceptibility to STDs. Vaccines against STDs must protect in these varied environments. This is different from other viruses (for example, polio) that enter the body through the nasal and oral cavities, where men and women are very similar. There is no evidence that polio vaccine offers different types of protection to men and women.

Another example of a sex-specific vaccine for an STD comes from Merck & Co., which in November 2002 launched a large, women-only Phase III trial of a vaccine against human papillomavirus (HPV), a disease causeing genital warts and cervical cancer . The company has conducted its trials almost entirely in women because cervical cancer, the most serious outcome of HPV infection, occurs only in women. (Merck also plans a later test of its vaccine in men, in whom HPV causes warts and anal cancer.)

Will gender prove important for AIDS vaccines? Right now, no one knows. The only way to get an answer is through large-scale trials that enroll enough men and women for genderspecific effects to become apparent.

The content in this issue of VAX is based on articles by Mark Boaz, Patricia Kahn, and Emily Bass, originally appearing in the February-April and May-July 2003 issues of IAVI Report.